Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUINIDEX vs MEMBRANEBLUE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.
Conversion and prevention of atrial fibrillation/flutter,Maintenance of sinus rhythm after cardioversion,Treatment of ventricular arrhythmias (off-label)
Treatment of acquired methemoglobinemia,Diagnostic staining (e.g., parathyroid glands, lymphatic mapping),Off-label: Refractory vasoplegic shock, prevention of ifosfamide neurotoxicity
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
Terminal elimination half-life 2.5-3.5 hours in adults; prolonged in hepatic or renal impairment (up to 6-8 hours).
Primarily hepatic via CYP3A4 (major) and CYP2C9 (minor) to active metabolites (3-hydroxyquinidine, quinidine-N-oxide); also renal excretion of unchanged drug (20%).
Reduced by NADPH-dependent methemoglobin reductase to leukomethylene blue; excreted in urine and bile.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Renal: approximately 60-70% unchanged; biliary/fecal: 20-30% as conjugated metabolites; minor pulmonary excretion.
80-90% bound to plasma proteins: primarily albumin and alpha-1-acid glycoprotein.
Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein.
2-4 L/kg; extensive tissue distribution with high affinity for myocardium (tissue-to-plasma ratio >10).
0.35-0.45 L/kg, indicating primarily extracellular distribution.
70-80% for immediate-release oral; 50-70% for sustained-release formulations due to first-pass metabolism; absorption reduced by food.
Intravenous: 100% (only route); oral bioavailability negligible (<1%) due to extensive first-pass metabolism.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours. Cr Cl 10-29 m L/min: administer 50% of normal dose every 8 hours. Cr Cl <10 m L/min: administer 50% of normal dose every 12 hours.
No specific dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to limited data.
Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50%; monitor levels. Child-Pugh class C: contraindicated or use with extreme caution; reduce dose by 75% with therapeutic drug monitoring.
No specific dose adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential for altered metabolism.
Oral: 15-60 mg/kg/day in 4-5 divided doses; maximum single dose 600 mg. For chronic suppression: start 30 mg/kg/day in 4-5 divided doses.
2 mg/kg intravenously once, not to exceed 100 mg total dose; repeat dosing not typically recommended.
Start at lower end of dosing range (200 mg every 8 hours) due to decreased hepatic and renal function; adjust based on plasma levels and QT interval monitoring.
No specific dose adjustment required; monitor for renal function and fluid overload due to age-related physiological changes.
Increased mortality in treatment of non-life-threatening ventricular arrhythmias; proarrhythmic effects (torsades de pointes).
Serotonin syndrome with concurrent serotonergic drugs (especially SSRIs, SNRIs, MAOIs); discontinue serotonergic agents prior to use; do not use in patients taking serotonergic drugs.
Proarrhythmia (torsades de pointes), hepatotoxicity, cinchonism, hypersensitivity reactions, worsening of heart failure, digitalis toxicity, incomplete AV block, electrolyte disturbances.
Risk of serotonin syndrome when used with serotonergic agents; may cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; may cause interferences with pulse oximetry readings; monitor methemoglobin levels; may cause fetal harm.
Hypersensitivity to quinidine or cinchona alkaloids, complete AV block or severe intraventricular conduction defects, myasthenia gravis, history of thrombocytopenia with quinidine, concurrent use with drugs that prolong QT interval (unless absolutely necessary).
Known hypersensitivity to methylene blue; concurrent use with serotonergic drugs (SSRIs, SNRIs, MAOIs); severe G6PD deficiency.
Grapefruit juice increases quinidine bioavailability and serum levels, raising toxicity risk. Avoid grapefruit and grapefruit juice. Alkaline foods (e.g., antacids, milk) may increase quinidine absorption. High-sodium diet may enhance potassium loss and worsen arrhythmias. Avoid excessive caffeine or stimulants.
No known food interactions. Avoid alcohol consumption for 24 hours post-administration due to potential increased sedative effects.
First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal QT prolongation, neonatal thrombocytopenia, and tachycardia. Fetal distress may occur. Avoid if alternative exists, but if needed, monitor fetal ECG and heart rate.
Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.
Quinidine is excreted into breast milk. M/P ratio reported as 0.57–0.78. Amount is low, but monitor infant for arrhythmias, bruising, and bleeding. Generally considered compatible with breastfeeding if maternal monitoring is done.
Breastfeeding safety not established. M/P ratio unknown. Use caution during lactation due to potential for excretion.
Increased volume of distribution may require dose increases. Protein binding decreases, potentially lowering total drug concentrations. Monitor free drug levels if possible. adjust dose based on therapeutic drug monitoring and clinical response. Close monitoring recommended.
No dose adjustment required based on pharmacokinetic changes during pregnancy.
Quinidine (as Quinidex) is a class Ia antiarrhythmic; monitor QRS and QT intervals due to risk of torsades de pointes. It also has anticholinergic properties, causing diarrhea in up to 50% of patients, which can be dose-limiting. Drug interactions are critical: quinidine inhibits CYP2D6, increasing levels of digoxin, warfarin, and many beta-blockers. Consider checking serum quinidine levels (therapeutic: 2-6 mcg/m L) and ECG if initiating or adjusting dose.
MEMBRANEBLUE (methylene blue) 1% solution is used intravenously for methemoglobinemia and as an optical imaging agent. Monitor for serotonergic toxicity if combined with SSRIs/SNRIs due to MAO inhibition. Do not exceed 7 mg/kg total dose to avoid severe adverse effects. Use with caution in G6PD deficiency due to risk of hemolytic anemia.
Take exactly as prescribed; do not double dose if missed.,Avoid grapefruit juice as it can increase quinidine levels and toxicity.,Report new or worsening palpitations, dizziness, syncope, or irregular heartbeat immediately.,May cause diarrhea; contact your prescriber if diarrhea becomes severe or persistent.,Quinidine can cause blurred vision, tinnitus, or headache; report these to your doctor.,Avoid over-the-counter medications without consulting your doctor (especially antacids, antihistamines, and cold remedies).
This medication may cause your urine, stool, or skin to turn blue-green, which is harmless and temporary.,Report any severe headache, chest pain, or difficulty breathing immediately.,Avoid taking medications for depression, anxiety, or migraine (SSRIs, SNRIs, MAOIs) within 24 hours of receiving MEMBRANEBLUE unless directed by your doctor.,If you have a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, inform your healthcare provider before treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUINIDEX vs MEMBRANEBLUE, answered by our medical review team.
QUINIDEX is a Antiarrhythmic Agent that works by Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.. MEMBRANEBLUE is a Ophthalmic Dye that works by Methylene blue (Membraneblue) is a selective inhibitor of guanylyl cyclase, thereby reducing cyclic guanosine monophosphate (c GMP) levels. It also acts as an electron carrier in the reduction of methemoglobin to hemoglobin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUINIDEX and MEMBRANEBLUE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUINIDEX is: Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.. The standard adult dose of MEMBRANEBLUE is: 2 mg/kg intravenously once, administered over 30 minutes; may repeat once if clinically indicated after 30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUINIDEX and MEMBRANEBLUE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUINIDEX is classified as Category C. First trimester: Limited data, but quinidine crosses placenta. No clear increase in major malformations after first trimester exposure. Second and third trimesters: Risk of fetal Q. MEMBRANEBLUE is classified as Category C. Current evidence indicates no increased risk of major congenital malformations with prenatal exposure. No known fetal risks during any trimester. However, human data are limited.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.